TABLE 2.
Infectious profiles and clinical outcomes of the patients who underwent TDM.
| Prognosis | Infection sites | Bacteria types | Total | ||||||
| Lung | Lung + Others | Abdomen | Others | AB | AB + KP/E. coli | KP | Others | ||
| All (%) | 32 (55.17) | 10 (17.24) | 4 (6.90) | 12 (20.69) | 15 (25.86) | 9 (15.52) | 4 (6.9) | 30 (51.72) | 58 (100) |
| Effective (%) | 15 (46.88) | 7 (70.00) | 3 (75.00) | 10 (83.33) | 8 (53.33) | 4 (44.44) | 2 (50.00) | 20 (66.67) | 34 (58.62) |
| Ineffective (%) | 7 (21.88) | 1 (10.00) | 0 (0.00) | 0 (0.00) | 6 (40%) | 1 (11.11) | 0 (0.00) | 1 (3.33) | 8 (13.79) |
| Death (%) | 10 (31.25) | 2 (20.00) | 1 (20.00) | 2 (16.67) | 1 (6.67) | 4 (44.44) | 2 (50.00) | 9 (30.00) | 16 (27.59) |
TDM, therapeutic drug monitoring; AB, Acinetobacter baumannii; KP, Klebsiella pneumoniae; E. coli, Escherichia coli.